US stock futures flat after Wall St drops on Trump tariffs, soft jobs data
CHICAGO - Cosmos Health Inc. (NASDAQ:COSM), a global healthcare group, has been granted an additional 180-day period by the Nasdaq Stock Market to meet the minimum bid price requirement, extending the deadline to November 3, 2025. The company initially received notice of non-compliance on November 6, 2024, when its stock price remained below $1.00 for 30 consecutive business days. Currently trading at $0.42, the stock has shown recent momentum with an 11.6% gain over the past week, according to InvestingPro data.
The extended compliance period is a result of Cosmos Health continuing to satisfy all other applicable Nasdaq Capital Market listing standards, except for the bid price rule. The company aims to regain compliance during this period. If Cosmos Health’s stock price reaches or exceeds $1.00 per share for a minimum of 10 consecutive business days, Nasdaq will confirm compliance and close the matter. InvestingPro analysis suggests the stock is currently undervalued, though investors should note the company’s significant debt burden and weak profit margins of 7.9%.
Greg Siokas, CEO of Cosmos Health, expressed confidence in meeting the listing requirements within the new timeframe and emphasized the company’s commitment to its strategic priorities and shareholder value. While the company reported a net loss in the last twelve months, InvestingPro analysts project profitability for the current fiscal year. Get access to 12 additional exclusive ProTips and comprehensive financial analysis by subscribing to InvestingPro.
Cosmos Health, established in Nevada in 2009, is involved in various healthcare sectors, including R&D, proprietary brands, manufacturing, distribution, and telehealth services. The company’s portfolio includes brands like Sky Premium Life®, Mediterranation®, and bio-bebe®. Its subsidiary, Cana Laboratories S.A., manufactures products under European GMP and is EMA-certified. Cosmos Health also distributes pharmaceuticals and parapharmaceuticals across Greece and the UK.
Moreover, the company has engaged in R&D partnerships to tackle health disorders such as obesity, diabetes, and cancer, and has ventured into the telehealth market through acquiring ZipDoctor, Inc. Cosmos Health is expanding its global reach, with operations in Europe, Asia, and North America.
The information provided in this article is based on a press release statement from Cosmos Health Inc.
In other recent news, Cosmos Health Inc. has announced several significant developments. The company reported a contract manufacturing agreement through its subsidiary Cana Laboratories with Pharmex S.A. for the production of 1.5 million units of the antiseptic drug AMBITASOL 1L over five years, enhancing its revenue generation capabilities. Cosmos Health also expanded its market reach by launching its Sky Premium Life food supplements in Albania, securing an initial order valued at $300,000 through a partnership with Pharma Cell. Additionally, the company postponed its planned securities offering, aligning this decision with the filing of its upcoming Annual Report. Cosmos Health is advancing its weight management device, CCX0722, towards clinical trials, with a market launch anticipated in the first half of 2026. In a move demonstrating confidence in the company’s future, CEO Greg Siokas increased his stake by purchasing over 1.4 million shares, totaling $526,000. These developments reflect Cosmos Health’s ongoing efforts to expand its product offerings and market presence.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.